Kendle Advances Early Stage Drug Development with ElMindA's Innovative Brain Network Activation Technology
CINCINNATI, June 15 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation (BNA) imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel. Exclusively licensed to Kendle's early stage development efforts, this innovative solution reveals electrophysiological neural networks by using an innovative set of signal processing and pattern recognition techniques that combine the high temporal resolution of EEG with the spatial resolution of fMRI. The result is a three-dimensional image of neuronal connectivity and synchronization providing sensitive, specific and reproducible data on drug effects essential for early stage development.
"This technology represents a sizeable step forward in our ability to evaluate the effectiveness of CNS drugs early in their development by directly and objectively observing the brain's response to them," said Ed Sellers, MD, PhD, FRCPC, FACP, Vice President, Early Stage, Kendle. "BNA is faster, less expensive and more accessible than other brain imaging solutions currently on the market because all scanning can be done in house. Ultimately this translates into powerful, abundant data and expedited go/no-go decisions for our customers, saving them time and money."
The BNA technology utilizes standard 64 electrode EEG and can be applied in any clinic by an E